Laboratory of Biochemical Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31-343 Kraków, Poland.
Pharmacol Rep. 2013;65(6):1498-505. doi: 10.1016/s1734-1140(13)71510-x.
G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins in the human genome and are the target of approximately half of all therapeutic drugs. For many years, GPCRs were thought to exist and function as monomeric units. However, during the past two decades, substantial biochemical, structural and functional evidence have indicated that GPCRs can associate and form heteromers that exhibit functional properties distinct from the corresponding monomers. The understanding of the unique pharmacological and functional properties of such heteromers is a major challenge for neuroscience, particularly given the abundant evidence suggesting that GPCR heteromers may play a crucial role in neuropsychiatric disorders. Herein, we present current data on the role of GPCR heterodimerization in neuropsychiatric disorders, with a focus on its potential implications in depression. The presented examples of pairs of receptors, with their specific pharmacological and functional properties, are likely to lead to novel effective strategies in antidepressant drug development. The currently available techniques for studying GPCR heterodimerization, both in vitro as well as in situ in native tissue, are also described.
G 蛋白偶联受体(GPCRs)是人类基因组中最大的膜蛋白家族,也是大约一半治疗药物的靶点。多年来,人们一直认为 GPCRs 以单体形式存在和发挥作用。然而,在过去的二十年中,大量的生化、结构和功能证据表明,GPCR 可以相互关联并形成异源二聚体,表现出与相应单体不同的功能特性。了解这种异源二聚体的独特药理学和功能特性是神经科学的主要挑战,特别是因为有大量证据表明 GPCR 异源二聚体可能在神经精神疾病中发挥关键作用。本文介绍了 GPCR 异源二聚化在神经精神疾病中的作用的最新数据,重点介绍了其在抑郁症中的潜在意义。所呈现的受体对及其特定的药理学和功能特性,很可能为抗抑郁药物的开发带来新的有效策略。还描述了目前用于研究 GPCR 异源二聚化的技术,包括体外和原位在天然组织中的技术。